
Venture capital · Early stage · Est. 2015
V-Bio
Belgium-based life-sciences venture firm that both spins up new companies and backs young ones, mainly in drug discovery and development, with a European focus and two funds under management.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is V-Bio right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (ESMA register).
Latest investments
Rounds V-Bio joined, from press and the firm’s own posts.
Every round V-Bio joined
Round sizes, V-Bio’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company V-Bio backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet V-Bio
Events where V-Bio’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
V-Bio is based in Gent, Belgium. Its registered address is Pieter van Reysschootlaan 2/104, B-9051 Gent.
In 2015.
1 fund vehicle is on public registers (ESMA register), including V-Bio Fund 2.
Stages: Early stage. Sectors: Life sciences, Biotech. From the firm’s own website.
Looks for private companies with differentiated, high-impact technology tackling unmet needs, concentrating on therapeutics from discovery through development. Sources deals through a close tie with the research institute VIB as well as other institutes, entrepreneurs and corporate spin-outs, and contributes network and sector expertise beyond money. From the firm’s own website.
V-Bio lists 8 portfolio companies on its website, including Agomab, Aphea.Bio, Biodol, Confo Therapeutics and Flindr Therapeutics.
Firms whose websites list some of the same companies include Asabys Partners, BioGeneration Ventures and Excel Venture Management.
Know before V-Bio’s next round is announced.
PRO tracks V-Bio’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.